IONIS PHARMACEUTICALS INC

For the period ended Mar 31, 2024. Filed May 7, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2024 · Filed May 7, 2024

IONS$28.19-9.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations

(in thousands, except for per share amounts)

	Three Months Ended March 31,
	2024	2023
Revenue:
Commercial revenue:
SPINRAZA royalties	$38,455	$50,247
WAINUA royalties	1,125	—
Other commercial revenue	20,013	17,521
Total commercial revenue	59,593	67,768
Research and development revenue:
Collaborative agreement revenue	49,345	38,334
WAINUA joint development revenue	10,559	24,422
Total research and development revenue	59,904	62,756
Total revenue	119,497	130,524
Expenses:
Cost of sales	2,151	1,343
Research, development and patent	214,215	197,813
Selling, general and administrative	52,644	45,516
Total operating expenses	269,010	244,672
Loss from operations	(149,513)	(114,148)
Other income (expense):
Investment income	26,285	18,627
Interest expense	(4,151)	(1,608)
Interest expense related to sale of future royalties	(17,959)	(15,515)
Gain (loss) on investments	2,333	(529)
Other income	277	230
Loss before income tax expense	(142,728)	(112,943)
Income tax expense	(75)	(11,380)
Net loss	$(142,803)	$(124,323)
Basic and diluted net loss per share	$(0.98)	$(0.87)
Shares used in computing basic and diluted net loss per share	145,538	142,735

Index

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.